EstropipateEstrogen receptor agonist and OATP1B1 inhibitor CAS# 7280-37-7 |
- Fulvestrant
Catalog No.:BCC1081
CAS No.:129453-61-8
- (Z)-2-decenoic acid
Catalog No.:BCC1295
CAS No.:15790-91-7
- Bazedoxifene
Catalog No.:BCC1411
CAS No.:198481-32-2
- Bazedoxifene acetate
Catalog No.:BCC1412
CAS No.:198481-33-3
- (E)-2-Decenoic acid
Catalog No.:BCC1292
CAS No.:334-49-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 7280-37-7 | SDF | Download SDF |
PubChem ID | 5284555 | Appearance | Powder |
Formula | C22H32N2O5S | M.Wt | 436.56 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 36 mg/mL (82.46 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;piperazine | ||
SMILES | CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1 | ||
Standard InChIKey | HZEQBCVBILBTEP-ZFINNJDLSA-N | ||
Standard InChI | InChI=1S/C18H22O5S.C4H10N2/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;1-2-6-4-3-5-1/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);5-6H,1-4H2/t14-,15-,16+,18+;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Estrogen receptor agonist. Also inhibits organic anion transporting polypeptide 1B1 (OATP1B1) (IC50= 70 nM). |
Estropipate Dilution Calculator
Estropipate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2906 mL | 11.4532 mL | 22.9064 mL | 45.8127 mL | 57.2659 mL |
5 mM | 0.4581 mL | 2.2906 mL | 4.5813 mL | 9.1625 mL | 11.4532 mL |
10 mM | 0.2291 mL | 1.1453 mL | 2.2906 mL | 4.5813 mL | 5.7266 mL |
50 mM | 0.0458 mL | 0.2291 mL | 0.4581 mL | 0.9163 mL | 1.1453 mL |
100 mM | 0.0229 mL | 0.1145 mL | 0.2291 mL | 0.4581 mL | 0.5727 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Linderalactone
Catalog No.:BCN1251
CAS No.:728-61-0
- ICI 118,551 hydrochloride
Catalog No.:BCC4029
CAS No.:72795-01-8
- Mesulergine hydrochloride
Catalog No.:BCC7139
CAS No.:72786-12-0
- β-Funaltrexamine hydrochloride
Catalog No.:BCC6850
CAS No.:72786-10-8
- Senecivernine
Catalog No.:BCN2135
CAS No.:72755-25-0
- Odorinol
Catalog No.:BCN4284
CAS No.:72755-22-7
- Odorine
Catalog No.:BCN4283
CAS No.:72755-20-5
- 1-Ethoxycarbonyl-beta-carboline
Catalog No.:BCN3102
CAS No.:72755-19-2
- Swainsonine
Catalog No.:BCC7602
CAS No.:72741-87-8
- H-D-Lys-OH.HCl
Catalog No.:BCC2989
CAS No.:7274-88-6
- Ilicol
Catalog No.:BCN4282
CAS No.:72715-02-7
- Mollisorin A
Catalog No.:BCN7236
CAS No.:72704-04-2
- Panaxydol
Catalog No.:BCN3701
CAS No.:72800-72-7
- OSI-930
Catalog No.:BCC1253
CAS No.:728033-96-3
- Atanine
Catalog No.:BCN3317
CAS No.:7282-19-1
- Deoxyartemisinin
Catalog No.:BCN4285
CAS No.:72826-63-2
- MIRA-1
Catalog No.:BCC2409
CAS No.:72835-26-8
- 1-Benzyl-5-phenylbarbituric acid
Catalog No.:BCC8461
CAS No.:72846-00-5
- Echitoveniline
Catalog No.:BCN7490
CAS No.:72855-79-9
- Crocandine
Catalog No.:BCN2070
CAS No.:72855-83-5
- Agatharesinol
Catalog No.:BCN4594
CAS No.:7288-11-1
- CHIR-090
Catalog No.:BCC1477
CAS No.:728865-23-4
- Benzoyloxypeoniflorin
Catalog No.:BCN2799
CAS No.:72896-40-3
- 4-Propenylbrenzcatechin
Catalog No.:BCN3672
CAS No.:72898-29-4
Effects of estropipate treatment on plasma lipids and lipoprotein lipid composition in postmenopausal women.[Pubmed:1991799]
J Clin Endocrinol Metab. 1991 Feb;72(2):283-6.
It is generally believed that the cardioprotective benefit of long term treatment of postmenopausal women with estrogen results in part from its capacity to increase high density lipoprotein (HDL) and lower low density lipoprotein (LDL) concentrations. The extent to which the various estrogens employed in replacement treatment affect the composition of lipoproteins, however, is not known. For this reason, we have examined the impact of one such preparation, the synthetic estrone Estropipate (1.25 mg/day), on lipoprotein levels and composition in six postmenopausal women. After 6 months of treatment, whole plasma triglyceride (pretreatment, 135 +/- 63; posttreatment, 143 +/- 56 mg/dL), cholesterol (pretreatment, 232 +/- 14; posttreatment, 216 +/- 29 mg/dL), and HDL-C (pretreatment, 57.8 +/- 14.8; posttreatment, 55.6 +/- 13.2) were unchanged. However, plasma free (unesterified) cholesterol (FC) fell (pretreatment, 73.4 +/- 6.2; posttreatment, 53.7 +/- 9.3 mg/dL; P less than 0.05) and lecithin (L) rose significantly (pretreatment, 2.12 +/- 0.29; posttreatment, 2.47 +/- 0.34 mumol/mL; P less than 0.01). The consequence of these changes was a significant decline in the plasma FC/L ratio (pretreatment, 0.91 +/- 0.17; posttreatment, 0.68 +/- 0.12; P less than 0.01) to levels observed in healthy menstruating women. The calculated lipoprotein particle size was unchanged in very low density lipoproteins and increased significantly (P less than 0.05) in LDL after Estropipate therapy. Since qualitatively altered lipoproteins enriched in FC and an increased FC/L ratio in plasma are both associated with increased coronary risk, the improvement noted in these parameters after Estropipate therapy indicates that its use may be beneficial despite the lack of change in whole plasma lipids.
Estrogen regulation of the cytochrome P450 3A subfamily in humans.[Pubmed:15282264]
J Pharmacol Exp Ther. 2004 Nov;311(2):728-35.
This study examines the possible role of estrogen in regulating the expression of the human CYP3A subfamily: CYP3A4, CYP3A5, CYP3A7, and CYP3A43. To accomplish this goal, mRNA was quantified from human livers and endometrial samples, and total CYP3A protein levels were evaluated by Western immunoblot analysis of the liver samples. The human endometrial samples were from premenopausal and postmenopausal women. The premenopausal endometrium was either in the proliferative or secretory phase, whereas for the postmenopausal endometrium samples, the women had been treated with either a placebo or Estropipate, an estrogen substitute. After analyses, CYP3A4 mRNA was shown to have lower hepatic expression in females than in males. In the endometrium, CYP3A4 and CYP3A43 are down-regulated by estrogen, whereas CYP3A5 is expressed at higher levels during the secretory phase. CYP3A7 was not detected in the endometrium. In addition, the CYP3A subfamily showed increased mRNA expression in the liver as age increased. The expression levels of total CYP3A protein and total CYP3A mRNA showed good correlation. Despite apparent regulation of CYP3A4 mRNA expression by estrogen, the effects of estrogen may be overshadowed by additional regulators of gene expression.